Table III.
Group | WBC (×103) |
L % | N % | E % | M % | B % | RBC (×106) |
Reticulocyte % |
Hb (g %) |
HCT (PCV %) |
Protime (sec) |
Platelet count (×105) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Control (0 mg/kg) |
7.92±2.55 | 72.90±2.73 | 24.50±2.55 | 1.50±0.53 | 1.10±0.32 | 0.00±0.00 | 7.37±0.34 | 7.60±0.52 | 14.49±1.07 | 42.03±2.76 | 17.80±0.79 | 8.58±0.49 |
Low dose (100 mg/kg) |
7.99±2.06 | 73.50±2.51 | 23.30±2.31 | 1.60±0.52 | 1.60±0.52 | 0.00±0.00 | 7.65±0.40 | 7.50±0.53 | 14.70±0.75 | 42.86±2.07 | 18.00±0.67 | 7.73±0.73 |
Intermediate dose (500 mg/kg) |
7.24±2.36 | 73.10±2.81 | 24.40±2.80 | 1.30±0.48 | 1.20±0.42 | 0.00±0.00 | 8.26±0.29 | 7.50±0.53 | 14.85±0.54 | 43.60±1.68 | 17.60±0.52 | 8.41±0.79 |
High dose (1,000 mg/kg) |
7.56±2.03 | 74.80±2.82 | 22.70±2.45 | 1.30±0.48 | 1.20±0.42 | 0.00±0.00 | 7.17±0.67 | 7.50±0.53 | 14.30±0.61 | 42.72±1.92 | 18.00±0.67 | 8.28±0.63 |
Satellite control (0 mg/kg) |
8.34±1.27 | 73.60±1.95 | 24.00±1.22 | 1.40±0.55 | 1.40±0.55 | 0.00±0.00 | 7.67±0.38 | 7.40±0.55 | 13.72±0.53 | 41.02±1.75 | 17.60±0.89 | 8.08±1.20 |
High dose satellite (1,000 mg/kg) |
8.24±1.04 | 75.00±1.58 | 22.40±1.14 | 1.20±0.45 | 1.40±0.55 | 0.00±0.00 | 8.05±0.27 | 7.60±0.55 | 14.18±0.22 | 43.30±2.22 | 18.60±0.55 | 8.18±0.70 |
Analysis of variance was used for statistical analysis. P>0.05, compared with the respective control. No significant differences were observed between the test and control groups. WBC, white blood cell; L, lymphocytes; N, neutrophils; E, eosinophils; M, monocytes; B, basophils; RBC, red blood cell; Hb, hemoglobin; HCT, haematocrit.